Paras Healthcare Q2 FY27 Earnings Call Transcript Released
Paras Healthcare's Q2 FY27 results show a 23% YoY revenue increase to ₹511 crore and a 47% EBITDA jump to ₹120 crore. H1 FY27 revenue grew 25% to ₹981 crore. New hospitals are now EBITDA positive. Post-IPO, net debt reduced significantly due to ₹375 crore debt repayment.
The strong financial performance, successful integration of new facilities, and improved financial health indicate a significant positive impact on the company's outlook and investor confidence.
The company reported strong year-on-year growth in revenue and EBITDA, improved margins, and profitability in newer hospitals. The balance sheet has strengthened post-IPO with significant debt reduction.
Paras Healthcare Limited has released the transcript of its Earnings Conference Call held on November 06, 2026. The call discussed the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026.
During the call, the management highlighted strong year-on-year growth. For Q2 FY27, revenue from operations stood at ₹511 crore, a 23% increase, with Operating EBITDA at ₹120 crore, up 47%, and margins expanding by 390 basis points to 23.5%. Profit before tax was ₹54 crore, a 2.7 times increase, and Profit After Tax was ₹40 crore, a 3.3 times increase compared to the previous year.
For the half-year ended September 30, 2026, revenue grew 25% to ₹981 crore, and Operating EBITDA grew 58% to ₹225 crore. The growth was attributed to the ramp-up of new hospitals, improved clinical and surgical mix, and increased outpatient and inpatient volumes. New hospitals in Srinagar and Kanpur have turned profitable at the EBITDA level.
The company also discussed its strengthened balance sheet post-IPO, with ₹375 crore of the ₹500 crore fresh issue used to repay borrowings, significantly reducing net debt. Future growth is expected from the ramp-up of newer hospitals, disciplined new capacity additions including Ludhiana and a new unit in Gurgaon, and a focus on complex specialty work.
Management detailed performance across hospital cohorts: mature hospitals (Gurgaon, Patna, Panchkula, Darbhanga) saw revenue growth of 8.5% and EBITDA margins at 29.5%. Emerging hospitals (Ranchi, Udaipur) grew revenue by 27.2% with improving margins. New hospitals (Srinagar, Kanpur) showed significant revenue growth of 139% in Q2 and turned EBITDA positive.
Discussions also covered operational KPIs such as ARPOB, ALOS, and occupancy rates, which have shown significant improvement. The company aims to optimize its payor mix and enhance its case mix by focusing on high-end tertiary and quaternary care specialties, including liver and kidney transplants, and robotic surgeries. Expansion plans include adding approximately 200-250 beds in the near term and future capacities in Gurgaon and Ludhiana.
What to do with a filing like this
Paras Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Paras Healthcare Limited. Read the original for the full detail.